Levofloxacin Hemihydrate (CAS 100986-85-4) — formula C18H20FN3O4, molecular weight 361.4.
| CAS Number | 100986-85-4 |
|---|---|
| Molecular Formula | C18H20FN3O4 |
| Molecular Weight | 361.4 |
| Melting Point | 225-227C |
| LogP | 2.1 |
| Applications | Uses: MEDICATION, Use (kg, approx.) in Germany (2009): >7500, exact) in Germany (2009): 7956, Use (kg) in USA (2002): 45200, Consumption (g per capita, approx.) in Germany (2009): 0.0916, exact) in Germany (2009): 0.0972, Consumption (g per capita) in the USA (2002): 0.16, Excretion rate: 0.85, Calculated removal (%): 1.9, For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: <i>Corynebacterium<, i> species, <i>Staphylococus aureus<, i>, <i>Staphylococcus epidermidis<, <i>Streptococcus pneumoniae<, <i>Streptococcus<, i> (Groups C, F, G), Viridans group streptococci, <i>Acinetobacter lwoffii<, <i>Haemophilus influenzae<, <i>Serratia marcescens<, i>. Levofloxacin is a synthetic chemotherapeutic agent used to treat severe and life threatening bacterial infection (L1009)., Use Classification: Pharmaceuticals, Formulations, Preparations: Table: Levofloxacin Preparations [Table#7973], Parenteral Injection, for IV infusion: equivalent to levofloxacin 5 mg, mL (250, 500, or 750 mg) in 5% Dextrose, Levaquin in Dextrose Injection Premix (in flexible containers) (Ortho-McNeil)., Ophthalmic: Solution 0.5%, Quixin (Vistakon), Tavanic (levofloxacin, 250 and 500 mg film-coated tablets and 5mg, mL solution for infusion), General Manufacturing Information: The more active levo isomer of ofloxacin (a racemic mixture of D, L, -isomers) that has improved activity against gram-potitive pathogens (in particular against S. pneumoniae) compared to ciprofloxacin., Prepared as the hemihydrate, The methyl group at the C-3 position in the oxazine ring results in the formation of isoenantiomers, ofloxacin occurs as a racemic mixture of the two isomers. The S-(-)isomer is 8-128 times as active against susceptible gram-positive and gram-negative organisms as the R-(+)isomer and approximately twice as active as racemic ofloxacin. |
Documented applications: Uses: MEDICATION, Use (kg, approx.) in Germany (2009): >7500, exact) in Germany (2009): 7956, Use (kg) in USA (2002): 45200, Consumption (g per capita, approx.) in Germany (2009): 0.0916, exact) in Germany (2009): 0.0972, Consumption (g per capita) in the USA (2002): 0.16, Excretion rate: 0.85, Calculated removal (%): 1.9, For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: <i>Corynebacterium<, i> species, <i>Staphylococus aureus<, i>, <i>Staphylococcus epidermidis<, <i>Streptococcus pneumoniae<, <i>Streptococcus<, i> (Groups C, F, G), Viridans group streptococci, <i>Acinetobacter lwoffii<, <i>Haemophilus influenzae<, <i>Serratia marcescens<, i>. Levofloxacin is a synthetic chemotherapeutic agent used to treat severe and life threatening bacterial infection (L1009)., Use Classification: Pharmaceuticals, Formulations, Preparations: Table: Levofloxacin Preparations [Table#7973], Parenteral Injection, for IV infusion: equivalent to levofloxacin 5 mg, mL (250, 500, or 750 mg) in 5% Dextrose, Levaquin in Dextrose Injection Premix (in flexible containers) (Ortho-McNeil)., Ophthalmic: Solution 0.5%, Quixin (Vistakon), Tavanic (levofloxacin, 250 and 500 mg film-coated tablets and 5mg, mL solution for infusion), General Manufacturing Information: The more active levo isomer of ofloxacin (a racemic mixture of D, L, -isomers) that has improved activity against gram-potitive pathogens (in particular against S. pneumoniae) compared to ciprofloxacin., Prepared as the hemihydrate, The methyl group at the C-3 position in the oxazine ring results in the formation of isoenantiomers, ofloxacin occurs as a racemic mixture of the two isomers. The S-(-)isomer is 8-128 times as active against susceptible gram-positive and gram-negative organisms as the R-(+)isomer and approximately twice as active as racemic ofloxacin..
Levofloxacin Hemihydrate is a chemical compound with CAS registry number 100986-85-4 and molecular formula C18H20FN3O4 (molecular weight 361.4).
CAS number: 100986-85-4
Its molecular formula C18H20FN3O4 comprises 18 C, 20 H, 1 F, 3 N, 4 O atoms.
Also known as: Levofloxacin Hemihydrate · 左氧氟沙星半水合物 · Levofloxacin
The CAS registry number of Levofloxacin Hemihydrate is 100986-85-4.
Molecular formula C18H20FN3O4, molecular weight 361.4.
It is also registered under: Levofloxacin Hemihydrate, 左氧氟沙星半水合物, Levofloxacin.
Recorded applications: Uses: MEDICATION, Use (kg, approx.) in Germany (2009): >7500, exact) in Germany (2009): 7956, Use (kg) in USA (2002): 45200, Consumption (g per capita, approx.) in Germany (2009): 0.0916, exact) in Germany (2009): 0.0972, Consumption (g per capita) in the USA (2002): 0.16, Excretion rate: 0.85, Calculated removal (%): 1.9, For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: <i>Corynebacterium<, i> species, <i>Staphylococus aureus<, i>, <i>Staphylococcus epidermidis<, <i>Streptococcus pneumoniae<, <i>Streptococcus<, i> (Groups C, F, G), Viridans group streptococci, <i>Acinetobacter lwoffii<, <i>Haemophilus influenzae<, <i>Serratia marcescens<, i>. Levofloxacin is a synthetic chemotherapeutic agent used to treat severe and life threatening bacterial infection (L1009)., Use Classification: Pharmaceuticals, Formulations, Preparations: Table: Levofloxacin Preparations [Table#7973], Parenteral Injection, for IV infusion: equivalent to levofloxacin 5 mg, mL (250, 500, or 750 mg) in 5% Dextrose, Levaquin in Dextrose Injection Premix (in flexible containers) (Ortho-McNeil)., Ophthalmic: Solution 0.5%, Quixin (Vistakon), Tavanic (levofloxacin, 250 and 500 mg film-coated tablets and 5mg, mL solution for infusion), General Manufacturing Information: The more active levo isomer of ofloxacin (a racemic mixture of D, L, -isomers) that has improved activity against gram-potitive pathogens (in particular against S. pneumoniae) compared to ciprofloxacin., Prepared as the hemihydrate, The methyl group at the C-3 position in the oxazine ring results in the formation of isoenantiomers, ofloxacin occurs as a racemic mixture of the two isomers. The S-(-)isomer is 8-128 times as active against susceptible gram-positive and gram-negative organisms as the R-(+)isomer and approximately twice as active as racemic ofloxacin..
Independent reference data for Levofloxacin Hemihydrate (CAS 100986-85-4), compiled from public chemistry databases.
| CAS Registry Number | 100986-85-4 |
|---|---|
| PubChem CID | 149096 |
| Molecular formula | C18H20FN3O4 |
| IUPAC name | (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| UNII (FDA) | RIX4E89Y14 |
| Molecular Weight | 361.4 |
|---|---|
| XLogP3 | -0.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 2 |
| Exact Mass | 361.14378429 |
| Monoisotopic Mass | 361.14378429 |
| Topological Polar Surface Area | 73.3 |
| Heavy Atom Count | 26 |
| Melting Point | 225-227C |
|---|---|
| Melting Point | 225-227 °C (decomposes) |
| LogP | 2.1 |
| LogP | log Kow = -0.39 |
| Dissociation Constants | 8.12 |
| Dissociation Constants | 6.1 |
| Dissociation Constants | 8.6 |
| Dissociation Constants | 6.25 |
LEVOFLOXACIN; 100986-85-4; Levaquin; Quixin; (-)-Ofloxacin; Iquix; Cravit; (S)-Ofloxacin; Levofloxacine; Tavanic; Levofloxacino; Levofloxacinum; Elequine; Oftaquix; L-Ofloxacin; Floxacin
| Reported hazard statements | H302 (98.3%), H317 (96%), H334 (97.1%), H361 (54.6%), H362 (53.4%) |
|---|
H302 (98.3%): Harmful if swallowed [Warning Acute toxicity, oral]
H317 (96%): May cause an allergic skin reaction [Warning Sensitization, Skin]
Levofloxacin · CAS 100986-85-4 · C18H20FN3O4. UNII RIX4E89Y14. Melting Point: 225-227C; Melting Point: 225-227 °C (decomposes); LogP: 2.1.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 左氧氟沙星